The activation of pRb by the treatment of lung cancer A549 and SK-MES-1 cells with palbociclib, a CDK4/6 inhibitor, increased the expression of MEG3, while the knockdown of pRb/p107 attenuated MEG3 gene expression [44]. The gene discussed is MEG3; the disease is lung cancer.